Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pancreaticoduodenectomy | 41 | 2022 | 62 | 5.260 |
Why?
|
Pancreatic Neoplasms | 46 | 2023 | 331 | 4.330 |
Why?
|
Pancreatitis, Acute Necrotizing | 23 | 2022 | 24 | 3.750 |
Why?
|
Pancreatectomy | 36 | 2023 | 96 | 3.520 |
Why?
|
Carcinoma, Pancreatic Ductal | 20 | 2023 | 106 | 2.200 |
Why?
|
Postoperative Complications | 26 | 2023 | 1202 | 1.470 |
Why?
|
Laparoscopy | 13 | 2021 | 427 | 1.350 |
Why?
|
Pancreatic Ducts | 11 | 2020 | 30 | 1.310 |
Why?
|
Adenocarcinoma | 15 | 2022 | 323 | 1.300 |
Why?
|
Drainage | 15 | 2022 | 149 | 1.130 |
Why?
|
Retrospective Studies | 76 | 2023 | 6071 | 1.120 |
Why?
|
Pancreatic Fistula | 10 | 2021 | 18 | 1.060 |
Why?
|
Adenocarcinoma, Mucinous | 9 | 2019 | 30 | 1.000 |
Why?
|
Intestinal Fistula | 3 | 2020 | 10 | 0.900 |
Why?
|
Middle Aged | 89 | 2022 | 16317 | 0.890 |
Why?
|
Duodenal Diseases | 2 | 2020 | 14 | 0.860 |
Why?
|
Humans | 138 | 2023 | 59360 | 0.820 |
Why?
|
Sphincter of Oddi Dysfunction | 3 | 2023 | 3 | 0.810 |
Why?
|
Pancreatic Diseases | 7 | 2015 | 39 | 0.810 |
Why?
|
Mesenteric Veins | 2 | 2020 | 11 | 0.810 |
Why?
|
Female | 111 | 2022 | 30705 | 0.790 |
Why?
|
Pancreatitis | 6 | 2023 | 95 | 0.770 |
Why?
|
Aged | 66 | 2022 | 13416 | 0.740 |
Why?
|
Gallbladder | 12 | 2007 | 33 | 0.740 |
Why?
|
Male | 93 | 2022 | 27739 | 0.740 |
Why?
|
Gallstones | 3 | 2020 | 24 | 0.730 |
Why?
|
Patient Discharge | 3 | 2023 | 489 | 0.720 |
Why?
|
Nomograms | 1 | 2020 | 12 | 0.690 |
Why?
|
Pancreas | 7 | 2019 | 147 | 0.680 |
Why?
|
Vascular Fistula | 1 | 2020 | 8 | 0.680 |
Why?
|
Crohn Disease | 2 | 2020 | 106 | 0.670 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 69 | 0.670 |
Why?
|
Adult | 60 | 2022 | 15669 | 0.670 |
Why?
|
Patient Readmission | 7 | 2023 | 420 | 0.660 |
Why?
|
Venous Thrombosis | 5 | 2022 | 110 | 0.640 |
Why?
|
Cholangiocarcinoma | 8 | 2012 | 27 | 0.600 |
Why?
|
Choledochostomy | 1 | 2018 | 3 | 0.590 |
Why?
|
Common Bile Duct | 1 | 2018 | 19 | 0.590 |
Why?
|
Duodenum | 1 | 2018 | 42 | 0.580 |
Why?
|
Hepatectomy | 7 | 2022 | 60 | 0.580 |
Why?
|
Pancreatic Cyst | 6 | 2018 | 24 | 0.580 |
Why?
|
Treatment Outcome | 36 | 2023 | 5284 | 0.560 |
Why?
|
Bile Duct Neoplasms | 7 | 2012 | 42 | 0.560 |
Why?
|
Carcinoma, Papillary | 6 | 2019 | 35 | 0.540 |
Why?
|
Incidence | 19 | 2022 | 1237 | 0.530 |
Why?
|
Aged, 80 and over | 31 | 2021 | 5128 | 0.490 |
Why?
|
Debridement | 5 | 2022 | 30 | 0.480 |
Why?
|
Palliative Care | 8 | 2017 | 214 | 0.470 |
Why?
|
Bile Ducts, Intrahepatic | 6 | 2010 | 25 | 0.470 |
Why?
|
Digestive System Surgical Procedures | 3 | 2023 | 88 | 0.460 |
Why?
|
Length of Stay | 15 | 2021 | 775 | 0.450 |
Why?
|
Obesity | 10 | 2022 | 1166 | 0.430 |
Why?
|
Gastroparesis | 3 | 2019 | 8 | 0.420 |
Why?
|
Laparotomy | 3 | 2021 | 47 | 0.410 |
Why?
|
Gallbladder Diseases | 4 | 2007 | 26 | 0.410 |
Why?
|
Risk Factors | 20 | 2023 | 4984 | 0.410 |
Why?
|
Survival Rate | 16 | 2020 | 802 | 0.390 |
Why?
|
Blood Loss, Surgical | 3 | 2018 | 57 | 0.360 |
Why?
|
Liver Diseases | 2 | 2022 | 138 | 0.350 |
Why?
|
Neoplasm Invasiveness | 12 | 2018 | 250 | 0.350 |
Why?
|
Indiana | 10 | 2021 | 19 | 0.340 |
Why?
|
Tomography, X-Ray Computed | 10 | 2020 | 1526 | 0.340 |
Why?
|
Bile | 6 | 2019 | 19 | 0.330 |
Why?
|
Clinical Competence | 3 | 2020 | 683 | 0.330 |
Why?
|
Surgical Wound Infection | 4 | 2023 | 110 | 0.330 |
Why?
|
Pancreaticojejunostomy | 3 | 2017 | 5 | 0.320 |
Why?
|
Sphincterotomy, Transduodenal | 3 | 2023 | 4 | 0.320 |
Why?
|
Leptin | 8 | 2006 | 83 | 0.320 |
Why?
|
Insulin Resistance | 3 | 2007 | 392 | 0.310 |
Why?
|
Colorectal Neoplasms | 2 | 2023 | 263 | 0.310 |
Why?
|
Cholelithiasis | 4 | 2004 | 22 | 0.300 |
Why?
|
Muscle, Smooth | 3 | 2019 | 137 | 0.300 |
Why?
|
Gastrostomy | 3 | 2019 | 29 | 0.300 |
Why?
|
Biliary Tract Surgical Procedures | 2 | 2010 | 12 | 0.290 |
Why?
|
Prognosis | 12 | 2020 | 1600 | 0.290 |
Why?
|
Biliary Fistula | 2 | 2020 | 4 | 0.290 |
Why?
|
Follow-Up Studies | 14 | 2020 | 2337 | 0.280 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 4 | 2023 | 46 | 0.270 |
Why?
|
Prospective Studies | 12 | 2023 | 3067 | 0.270 |
Why?
|
Postoperative Care | 3 | 2018 | 114 | 0.270 |
Why?
|
Splenic Artery | 2 | 2020 | 8 | 0.270 |
Why?
|
Preoperative Care | 7 | 2017 | 180 | 0.260 |
Why?
|
Gallbladder Neoplasms | 1 | 2006 | 16 | 0.260 |
Why?
|
Hernia, Ventral | 2 | 2020 | 25 | 0.260 |
Why?
|
Splenectomy | 2 | 2019 | 41 | 0.260 |
Why?
|
Gallbladder Emptying | 5 | 2006 | 5 | 0.250 |
Why?
|
Neuroendocrine Tumors | 2 | 2019 | 21 | 0.250 |
Why?
|
Necrosis | 6 | 2022 | 140 | 0.240 |
Why?
|
Logistic Models | 6 | 2020 | 1232 | 0.230 |
Why?
|
Aneurysm, False | 2 | 2020 | 46 | 0.230 |
Why?
|
Intestinal Obstruction | 2 | 2020 | 49 | 0.230 |
Why?
|
Cholesterol | 8 | 2007 | 252 | 0.230 |
Why?
|
Insulin | 3 | 2006 | 674 | 0.220 |
Why?
|
Negative-Pressure Wound Therapy | 1 | 2023 | 12 | 0.210 |
Why?
|
Biliary Tract Neoplasms | 1 | 2002 | 8 | 0.200 |
Why?
|
Surgical Wound | 1 | 2023 | 10 | 0.200 |
Why?
|
Pain, Postoperative | 3 | 2022 | 141 | 0.200 |
Why?
|
Young Adult | 11 | 2020 | 4267 | 0.200 |
Why?
|
Analgesia | 1 | 2022 | 30 | 0.200 |
Why?
|
Cholangitis | 2 | 2019 | 10 | 0.200 |
Why?
|
Pancreatitis, Chronic | 3 | 2020 | 19 | 0.200 |
Why?
|
Neoplasm Staging | 7 | 2017 | 452 | 0.200 |
Why?
|
Dilatation, Pathologic | 2 | 2019 | 29 | 0.200 |
Why?
|
Cystadenoma, Mucinous | 2 | 2017 | 5 | 0.190 |
Why?
|
Colonic Diseases | 1 | 2022 | 34 | 0.190 |
Why?
|
Hyperamylasemia | 1 | 2021 | 1 | 0.190 |
Why?
|
Adolescent | 10 | 2020 | 5824 | 0.180 |
Why?
|
Cholangiopancreatography, Magnetic Resonance | 2 | 2014 | 9 | 0.180 |
Why?
|
Patient Selection | 7 | 2019 | 464 | 0.180 |
Why?
|
Disease Progression | 4 | 2022 | 1122 | 0.180 |
Why?
|
Hypertriglyceridemia | 1 | 2021 | 8 | 0.180 |
Why?
|
Internship and Residency | 2 | 2020 | 746 | 0.180 |
Why?
|
Ursodeoxycholic Acid | 1 | 2020 | 7 | 0.180 |
Why?
|
Portal Vein | 2 | 2022 | 38 | 0.180 |
Why?
|
Surgical Mesh | 1 | 2020 | 58 | 0.170 |
Why?
|
Lung Diseases | 1 | 2022 | 170 | 0.170 |
Why?
|
Gastrectomy | 1 | 2020 | 37 | 0.170 |
Why?
|
Pulmonary Embolism | 2 | 2020 | 170 | 0.170 |
Why?
|
Wound Closure Techniques | 1 | 2020 | 7 | 0.170 |
Why?
|
Anti-Bacterial Agents | 4 | 2019 | 735 | 0.170 |
Why?
|
Leukocytosis | 1 | 2019 | 11 | 0.170 |
Why?
|
Pancreatic Pseudocyst | 1 | 2019 | 12 | 0.170 |
Why?
|
Amylases | 2 | 2021 | 11 | 0.170 |
Why?
|
Peritoneal Lavage | 1 | 2019 | 4 | 0.160 |
Why?
|
Sphincterotomy, Endoscopic | 2 | 2023 | 7 | 0.160 |
Why?
|
Survivors | 1 | 2020 | 149 | 0.160 |
Why?
|
Emergencies | 1 | 2020 | 111 | 0.160 |
Why?
|
Nurse's Role | 1 | 2020 | 116 | 0.160 |
Why?
|
Activins | 1 | 2019 | 54 | 0.160 |
Why?
|
Positron-Emission Tomography | 3 | 2015 | 200 | 0.160 |
Why?
|
Constriction, Pathologic | 4 | 2020 | 112 | 0.160 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2020 | 78 | 0.160 |
Why?
|
Lipase | 2 | 2021 | 48 | 0.160 |
Why?
|
Biliary Tract Diseases | 1 | 2019 | 16 | 0.160 |
Why?
|
Workload | 1 | 2019 | 118 | 0.160 |
Why?
|
Stomach | 1 | 2019 | 83 | 0.160 |
Why?
|
Deoxycytidine | 2 | 2017 | 40 | 0.160 |
Why?
|
Analgesia, Epidural | 1 | 2019 | 28 | 0.160 |
Why?
|
Time Factors | 9 | 2019 | 3617 | 0.160 |
Why?
|
BRCA2 Protein | 1 | 2019 | 13 | 0.160 |
Why?
|
Cholecystokinin | 4 | 2006 | 9 | 0.150 |
Why?
|
Clostridium Infections | 1 | 2019 | 45 | 0.150 |
Why?
|
DNA Fingerprinting | 1 | 2018 | 6 | 0.150 |
Why?
|
Alcohol-Related Disorders | 1 | 2019 | 35 | 0.150 |
Why?
|
Dietary Carbohydrates | 3 | 2007 | 58 | 0.150 |
Why?
|
Travel | 1 | 2018 | 37 | 0.150 |
Why?
|
Cholecystectomy | 3 | 2007 | 31 | 0.150 |
Why?
|
Practice Patterns, Physicians' | 3 | 2022 | 687 | 0.150 |
Why?
|
Enteral Nutrition | 2 | 2019 | 54 | 0.150 |
Why?
|
BRCA1 Protein | 1 | 2019 | 54 | 0.150 |
Why?
|
Thrombosis | 1 | 2020 | 182 | 0.150 |
Why?
|
Cholestasis | 2 | 1996 | 53 | 0.150 |
Why?
|
Surgeons | 1 | 2021 | 161 | 0.150 |
Why?
|
Gastric Bypass | 1 | 2019 | 74 | 0.150 |
Why?
|
Survival Analysis | 6 | 2015 | 555 | 0.150 |
Why?
|
Perioperative Care | 1 | 2019 | 76 | 0.150 |
Why?
|
Choledocholithiasis | 1 | 2018 | 4 | 0.150 |
Why?
|
Analgesics | 1 | 2019 | 96 | 0.150 |
Why?
|
Cross Infection | 1 | 2019 | 149 | 0.150 |
Why?
|
Ambulatory Care | 1 | 2020 | 300 | 0.140 |
Why?
|
Liver Neoplasms | 1 | 2020 | 277 | 0.140 |
Why?
|
Gastric Mucosa | 1 | 2017 | 51 | 0.140 |
Why?
|
Medical History Taking | 1 | 2017 | 65 | 0.140 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 300 | 0.140 |
Why?
|
Cholecystitis | 2 | 2007 | 27 | 0.140 |
Why?
|
Peripheral Nerves | 1 | 2017 | 30 | 0.140 |
Why?
|
Hepatic Duct, Common | 1 | 2017 | 7 | 0.140 |
Why?
|
Patient Care Team | 2 | 2017 | 326 | 0.140 |
Why?
|
Jejunum | 1 | 2017 | 14 | 0.140 |
Why?
|
Abdominal Pain | 1 | 2018 | 94 | 0.140 |
Why?
|
Venous Thromboembolism | 1 | 2019 | 141 | 0.140 |
Why?
|
Cancer Pain | 1 | 2017 | 15 | 0.140 |
Why?
|
Carcinoembryonic Antigen | 2 | 1999 | 32 | 0.140 |
Why?
|
Proton Pump Inhibitors | 2 | 2015 | 34 | 0.140 |
Why?
|
Patient Safety | 1 | 2019 | 237 | 0.140 |
Why?
|
Anastomotic Leak | 1 | 2017 | 33 | 0.130 |
Why?
|
Liver Cirrhosis | 1 | 2018 | 163 | 0.130 |
Why?
|
Embolization, Therapeutic | 1 | 2020 | 308 | 0.130 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2017 | 39 | 0.130 |
Why?
|
Chemoradiotherapy | 1 | 2017 | 49 | 0.130 |
Why?
|
Radiotherapy | 1 | 2017 | 62 | 0.130 |
Why?
|
Patient Education as Topic | 1 | 2020 | 453 | 0.130 |
Why?
|
Diagnosis, Differential | 6 | 2020 | 937 | 0.130 |
Why?
|
Blood Glucose | 7 | 2007 | 461 | 0.130 |
Why?
|
Inpatients | 1 | 2018 | 291 | 0.130 |
Why?
|
Databases, Factual | 5 | 2018 | 813 | 0.130 |
Why?
|
Sphincter of Oddi | 3 | 2019 | 4 | 0.130 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2015 | 29 | 0.130 |
Why?
|
Fellowships and Scholarships | 1 | 2017 | 98 | 0.130 |
Why?
|
Lipoma | 1 | 2015 | 16 | 0.130 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 718 | 0.130 |
Why?
|
Biomarkers, Tumor | 4 | 2014 | 461 | 0.120 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2015 | 9 | 0.120 |
Why?
|
Financing, Organized | 1 | 2015 | 16 | 0.120 |
Why?
|
Surgical Stapling | 1 | 2015 | 12 | 0.120 |
Why?
|
Anti-Ulcer Agents | 1 | 2015 | 8 | 0.120 |
Why?
|
Intubation, Gastrointestinal | 3 | 2021 | 20 | 0.120 |
Why?
|
CA-19-9 Antigen | 3 | 2014 | 10 | 0.120 |
Why?
|
Publications | 1 | 2015 | 28 | 0.120 |
Why?
|
Common Bile Duct Neoplasms | 1 | 1995 | 5 | 0.120 |
Why?
|
Peptic Ulcer | 1 | 2015 | 20 | 0.120 |
Why?
|
Splenic Vein | 1 | 2014 | 2 | 0.120 |
Why?
|
Ampulla of Vater | 1 | 1995 | 12 | 0.120 |
Why?
|
Hyperlipidemias | 2 | 2006 | 34 | 0.120 |
Why?
|
Lymph Node Excision | 2 | 2006 | 38 | 0.120 |
Why?
|
Cystadenoma, Serous | 2 | 2005 | 4 | 0.120 |
Why?
|
Adenoma | 1 | 2014 | 64 | 0.110 |
Why?
|
Liver Abscess, Pyogenic | 1 | 2014 | 1 | 0.110 |
Why?
|
Lipids | 2 | 2007 | 300 | 0.110 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2014 | 4 | 0.110 |
Why?
|
Health Services Accessibility | 1 | 2018 | 521 | 0.110 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 220 | 0.110 |
Why?
|
Mutation | 2 | 2019 | 2456 | 0.110 |
Why?
|
Parasympatholytics | 1 | 2013 | 6 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2015 | 170 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 3 | 2023 | 676 | 0.110 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2013 | 19 | 0.110 |
Why?
|
Ultrasonography | 3 | 2020 | 459 | 0.110 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 1025 | 0.110 |
Why?
|
Faculty, Medical | 1 | 2015 | 192 | 0.110 |
Why?
|
Precancerous Conditions | 1 | 2014 | 70 | 0.110 |
Why?
|
Catheter Ablation | 1 | 2015 | 145 | 0.110 |
Why?
|
Bile Ducts | 1 | 2012 | 21 | 0.100 |
Why?
|
Animals | 18 | 2019 | 19651 | 0.100 |
Why?
|
Deep Sedation | 1 | 2012 | 4 | 0.100 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 406 | 0.100 |
Why?
|
Body Mass Index | 3 | 2019 | 831 | 0.100 |
Why?
|
Body Weight | 7 | 2007 | 368 | 0.100 |
Why?
|
Disease-Free Survival | 4 | 2016 | 228 | 0.100 |
Why?
|
Mice, Inbred C57BL | 10 | 2007 | 3231 | 0.100 |
Why?
|
Smoking | 1 | 2016 | 826 | 0.100 |
Why?
|
Liver | 3 | 2012 | 797 | 0.090 |
Why?
|
Natural Orifice Endoscopic Surgery | 1 | 2012 | 37 | 0.090 |
Why?
|
Antineoplastic Agents | 1 | 2017 | 631 | 0.090 |
Why?
|
Nitric Oxide Synthase | 2 | 2001 | 45 | 0.090 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2001 | 20 | 0.090 |
Why?
|
Chi-Square Distribution | 4 | 2019 | 409 | 0.090 |
Why?
|
Neoadjuvant Therapy | 2 | 2022 | 72 | 0.090 |
Why?
|
Reoperation | 3 | 2019 | 272 | 0.090 |
Why?
|
Crystallization | 6 | 2007 | 97 | 0.090 |
Why?
|
Mice | 13 | 2019 | 10292 | 0.090 |
Why?
|
Sensitivity and Specificity | 3 | 2018 | 1093 | 0.090 |
Why?
|
Anastomosis, Surgical | 3 | 2020 | 107 | 0.090 |
Why?
|
Treatment Failure | 2 | 2020 | 185 | 0.080 |
Why?
|
Robotics | 1 | 2010 | 69 | 0.080 |
Why?
|
Dietary Fats | 2 | 2007 | 173 | 0.080 |
Why?
|
Social Class | 1 | 2010 | 122 | 0.080 |
Why?
|
Endosonography | 3 | 2017 | 26 | 0.080 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 2 | 2019 | 18 | 0.080 |
Why?
|
Bile Ducts, Extrahepatic | 2 | 2006 | 3 | 0.080 |
Why?
|
Combined Modality Therapy | 3 | 2017 | 355 | 0.080 |
Why?
|
Operative Time | 2 | 2019 | 76 | 0.080 |
Why?
|
Lipid Metabolism | 2 | 2007 | 203 | 0.080 |
Why?
|
Cholesterol, Dietary | 2 | 2006 | 28 | 0.070 |
Why?
|
Adipose Tissue | 2 | 2007 | 283 | 0.070 |
Why?
|
Risk Assessment | 5 | 2019 | 1921 | 0.070 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 674 | 0.070 |
Why?
|
Cholangitis, Sclerosing | 2 | 1999 | 12 | 0.070 |
Why?
|
Dinoprostone | 1 | 2007 | 44 | 0.070 |
Why?
|
Azetidines | 1 | 2007 | 7 | 0.070 |
Why?
|
Morbidity | 2 | 2020 | 112 | 0.070 |
Why?
|
Anticholesteremic Agents | 1 | 2007 | 34 | 0.070 |
Why?
|
Statistics, Nonparametric | 4 | 2009 | 206 | 0.070 |
Why?
|
Gastric Outlet Obstruction | 1 | 2007 | 2 | 0.070 |
Why?
|
Resistin | 1 | 2007 | 6 | 0.070 |
Why?
|
Pain Measurement | 2 | 2019 | 327 | 0.070 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2007 | 31 | 0.070 |
Why?
|
Fibroblasts | 2 | 2019 | 377 | 0.070 |
Why?
|
Multivariate Analysis | 2 | 2014 | 902 | 0.070 |
Why?
|
Midwestern United States | 1 | 2006 | 24 | 0.070 |
Why?
|
Thiazolidinediones | 1 | 2006 | 50 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2010 | 326 | 0.060 |
Why?
|
Hospital Mortality | 2 | 2021 | 841 | 0.060 |
Why?
|
Biopsy, Fine-Needle | 2 | 2018 | 61 | 0.060 |
Why?
|
United States | 4 | 2020 | 7390 | 0.060 |
Why?
|
Gene Expression | 2 | 2019 | 809 | 0.060 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 266 | 0.060 |
Why?
|
Mice, Obese | 4 | 2006 | 80 | 0.060 |
Why?
|
Radiography, Abdominal | 1 | 2005 | 27 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2021 | 1051 | 0.060 |
Why?
|
Dissection | 1 | 2005 | 45 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2006 | 192 | 0.060 |
Why?
|
Cystadenoma | 1 | 2004 | 6 | 0.060 |
Why?
|
Intestine, Small | 1 | 2005 | 77 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 4 | 2019 | 2060 | 0.060 |
Why?
|
Cohort Studies | 4 | 2011 | 2374 | 0.060 |
Why?
|
Pylorus | 1 | 2004 | 10 | 0.060 |
Why?
|
Acetylcholine | 4 | 2006 | 41 | 0.060 |
Why?
|
Myocytes, Smooth Muscle | 1 | 2004 | 57 | 0.060 |
Why?
|
Adenoma, Islet Cell | 1 | 2003 | 4 | 0.060 |
Why?
|
Preoperative Period | 2 | 2017 | 61 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2017 | 75 | 0.050 |
Why?
|
Recurrence | 3 | 2014 | 603 | 0.050 |
Why?
|
Severity of Illness Index | 2 | 2022 | 1479 | 0.050 |
Why?
|
Mice, Inbred NOD | 1 | 2004 | 516 | 0.050 |
Why?
|
Carcinoma | 1 | 2004 | 115 | 0.050 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 43 | 0.050 |
Why?
|
Stents | 1 | 2007 | 461 | 0.050 |
Why?
|
Muscle Contraction | 2 | 2019 | 197 | 0.050 |
Why?
|
Diet | 1 | 2006 | 497 | 0.050 |
Why?
|
Diabetes Mellitus | 2 | 2004 | 515 | 0.050 |
Why?
|
Acute Disease | 1 | 2023 | 660 | 0.050 |
Why?
|
Biomarkers | 2 | 2019 | 1306 | 0.050 |
Why?
|
Ileum | 1 | 2001 | 20 | 0.050 |
Why?
|
Organ Size | 3 | 2007 | 164 | 0.050 |
Why?
|
Decompression | 1 | 2021 | 1 | 0.050 |
Why?
|
Gastric Emptying | 1 | 2021 | 6 | 0.050 |
Why?
|
North America | 2 | 2012 | 106 | 0.050 |
Why?
|
Gastric Fistula | 1 | 2020 | 4 | 0.040 |
Why?
|
Exocrine Pancreatic Insufficiency | 1 | 2020 | 7 | 0.040 |
Why?
|
Splanchnic Circulation | 1 | 2020 | 16 | 0.040 |
Why?
|
Propensity Score | 1 | 2021 | 144 | 0.040 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2020 | 26 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 2001 | 83 | 0.040 |
Why?
|
Factor Xa Inhibitors | 1 | 2020 | 34 | 0.040 |
Why?
|
Immunohistochemistry | 2 | 2019 | 847 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 396 | 0.040 |
Why?
|
Genotype | 1 | 2002 | 617 | 0.040 |
Why?
|
Triglycerides | 3 | 2007 | 231 | 0.040 |
Why?
|
Kidney Neoplasms | 1 | 2001 | 126 | 0.040 |
Why?
|
Health Plan Implementation | 1 | 2020 | 40 | 0.040 |
Why?
|
Herniorrhaphy | 1 | 2020 | 69 | 0.040 |
Why?
|
Retreatment | 1 | 2020 | 46 | 0.040 |
Why?
|
Leukocyte Count | 1 | 2019 | 97 | 0.040 |
Why?
|
Odds Ratio | 1 | 2022 | 745 | 0.040 |
Why?
|
Heparin | 1 | 2020 | 111 | 0.040 |
Why?
|
Efficiency | 1 | 2019 | 37 | 0.040 |
Why?
|
Cachexia | 1 | 2019 | 9 | 0.040 |
Why?
|
Activin Receptors, Type II | 1 | 2019 | 9 | 0.040 |
Why?
|
Colectomy | 1 | 2020 | 104 | 0.040 |
Why?
|
Syndrome | 1 | 2019 | 170 | 0.040 |
Why?
|
Body Weights and Measures | 1 | 2019 | 33 | 0.040 |
Why?
|
Intraoperative Care | 1 | 2019 | 36 | 0.040 |
Why?
|
Actuarial Analysis | 2 | 1999 | 17 | 0.040 |
Why?
|
Lymphoma | 1 | 2000 | 99 | 0.040 |
Why?
|
Muscular Atrophy | 1 | 2019 | 25 | 0.040 |
Why?
|
Failure to Thrive | 1 | 2019 | 7 | 0.040 |
Why?
|
Centralized Hospital Services | 1 | 2018 | 5 | 0.040 |
Why?
|
Fatigue | 1 | 2019 | 103 | 0.040 |
Why?
|
Genes, ras | 1 | 1998 | 27 | 0.040 |
Why?
|
Nurses | 1 | 2020 | 102 | 0.040 |
Why?
|
Reference Values | 1 | 2019 | 326 | 0.040 |
Why?
|
Quality of Life | 2 | 2023 | 1137 | 0.040 |
Why?
|
Islets of Langerhans | 1 | 2020 | 271 | 0.040 |
Why?
|
Genes, p53 | 1 | 1998 | 52 | 0.040 |
Why?
|
Muscle Fibers, Skeletal | 1 | 2019 | 87 | 0.040 |
Why?
|
Hospitals, High-Volume | 1 | 2018 | 32 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2019 | 65 | 0.040 |
Why?
|
Age Factors | 2 | 2016 | 1504 | 0.040 |
Why?
|
Heterozygote | 1 | 2019 | 161 | 0.040 |
Why?
|
Chronic Pain | 1 | 2020 | 134 | 0.040 |
Why?
|
Anticoagulants | 1 | 2022 | 477 | 0.040 |
Why?
|
Progesterone | 1 | 1999 | 158 | 0.040 |
Why?
|
Interstitial Cells of Cajal | 1 | 2017 | 2 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2017 | 5 | 0.040 |
Why?
|
Genetic Testing | 1 | 2019 | 126 | 0.040 |
Why?
|
Heme Oxygenase-1 | 1 | 2017 | 18 | 0.040 |
Why?
|
Stem Cell Factor | 1 | 2017 | 26 | 0.040 |
Why?
|
Clinical Decision-Making | 1 | 2019 | 146 | 0.040 |
Why?
|
Program Evaluation | 1 | 2020 | 470 | 0.040 |
Why?
|
Neoplasm Grading | 1 | 2017 | 79 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2022 | 483 | 0.040 |
Why?
|
Anoctamin-1 | 1 | 2017 | 16 | 0.040 |
Why?
|
Conversion to Open Surgery | 1 | 2017 | 7 | 0.040 |
Why?
|
Obesity, Morbid | 1 | 2019 | 92 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2019 | 715 | 0.040 |
Why?
|
Disease Management | 1 | 2019 | 221 | 0.040 |
Why?
|
Failure to Rescue, Health Care | 1 | 2017 | 4 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2019 | 2050 | 0.030 |
Why?
|
Endoscopy | 1 | 2017 | 98 | 0.030 |
Why?
|
Random Allocation | 2 | 2012 | 192 | 0.030 |
Why?
|
Fatty Acids, Nonesterified | 2 | 2007 | 56 | 0.030 |
Why?
|
Phospholipids | 2 | 2007 | 78 | 0.030 |
Why?
|
Choledochal Cyst | 1 | 1996 | 3 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2007 | 446 | 0.030 |
Why?
|
Universities | 1 | 2017 | 144 | 0.030 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 277 | 0.030 |
Why?
|
Dogs | 2 | 2012 | 314 | 0.030 |
Why?
|
Surgery Department, Hospital | 1 | 2015 | 20 | 0.030 |
Why?
|
Kidney Diseases | 1 | 2017 | 169 | 0.030 |
Why?
|
Quality of Health Care | 1 | 2019 | 510 | 0.030 |
Why?
|
Neuropeptide Y | 2 | 2006 | 12 | 0.030 |
Why?
|
Cell Line, Tumor | 1 | 2019 | 1370 | 0.030 |
Why?
|
Histamine H2 Antagonists | 1 | 2015 | 10 | 0.030 |
Why?
|
Jejunostomy | 2 | 2010 | 7 | 0.030 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2015 | 111 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2014 | 46 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2010 | 58 | 0.030 |
Why?
|
Hospitalization | 1 | 2022 | 1290 | 0.030 |
Why?
|
Early Termination of Clinical Trials | 1 | 2014 | 5 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2014 | 92 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2014 | 40 | 0.030 |
Why?
|
Neurotransmitter Agents | 2 | 2004 | 41 | 0.030 |
Why?
|
False Positive Reactions | 1 | 2014 | 76 | 0.030 |
Why?
|
Drug Resistance | 2 | 2004 | 95 | 0.030 |
Why?
|
Quality Improvement | 1 | 2017 | 416 | 0.020 |
Why?
|
Peptide Fragments | 2 | 2006 | 400 | 0.020 |
Why?
|
Decision Support Techniques | 1 | 2014 | 179 | 0.020 |
Why?
|
RNA, Messenger | 1 | 2017 | 1465 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2007 | 1561 | 0.020 |
Why?
|
Sciuridae | 2 | 2001 | 3 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1995 | 677 | 0.020 |
Why?
|
Ligation | 1 | 2011 | 33 | 0.020 |
Why?
|
Heart Failure | 1 | 2019 | 853 | 0.020 |
Why?
|
Health Care Costs | 1 | 2012 | 203 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 705 | 0.020 |
Why?
|
Algorithms | 2 | 2010 | 976 | 0.020 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2011 | 98 | 0.020 |
Why?
|
Down-Regulation | 2 | 2001 | 306 | 0.020 |
Why?
|
Fluorouracil | 1 | 2010 | 55 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2012 | 525 | 0.020 |
Why?
|
Florida | 1 | 2010 | 42 | 0.020 |
Why?
|
Blotting, Western | 2 | 2001 | 584 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2011 | 589 | 0.020 |
Why?
|
Contraindications | 1 | 2009 | 46 | 0.020 |
Why?
|
Signal Transduction | 1 | 2019 | 2902 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2011 | 306 | 0.020 |
Why?
|
Postoperative Period | 1 | 2009 | 127 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 297 | 0.020 |
Why?
|
Poverty | 1 | 2010 | 281 | 0.020 |
Why?
|
Ezetimibe | 1 | 2007 | 6 | 0.020 |
Why?
|
Cholesterol Esters | 1 | 2007 | 10 | 0.020 |
Why?
|
Viscera | 1 | 2007 | 10 | 0.020 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 74 | 0.020 |
Why?
|
Sodium | 1 | 2007 | 60 | 0.020 |
Why?
|
Osmolar Concentration | 1 | 2007 | 88 | 0.020 |
Why?
|
Cholinergic Agents | 1 | 2006 | 9 | 0.020 |
Why?
|
Decision Making | 1 | 2010 | 395 | 0.020 |
Why?
|
Angiography | 1 | 2007 | 146 | 0.020 |
Why?
|
Comorbidity | 1 | 2010 | 1078 | 0.020 |
Why?
|
Butter | 1 | 2006 | 1 | 0.020 |
Why?
|
Radiography, Interventional | 1 | 2007 | 72 | 0.020 |
Why?
|
Mice, Inbred Strains | 1 | 2006 | 179 | 0.020 |
Why?
|
Barium Sulfate | 1 | 2005 | 18 | 0.020 |
Why?
|
Enema | 1 | 2005 | 12 | 0.020 |
Why?
|
Mice, Mutant Strains | 1 | 2004 | 297 | 0.010 |
Why?
|
Spleen | 1 | 2005 | 480 | 0.010 |
Why?
|
Phenotype | 1 | 2007 | 1137 | 0.010 |
Why?
|
Vacuoles | 1 | 2003 | 26 | 0.010 |
Why?
|
Cytokines | 1 | 2007 | 912 | 0.010 |
Why?
|
Diabetes Complications | 1 | 2003 | 100 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 806 | 0.010 |
Why?
|
Contrast Media | 1 | 2005 | 408 | 0.010 |
Why?
|
Receptors, Vasoactive Intestinal Peptide | 1 | 2001 | 1 | 0.010 |
Why?
|
Nitroarginine | 1 | 2001 | 2 | 0.010 |
Why?
|
Nitric Oxide Synthase Type I | 1 | 2001 | 6 | 0.010 |
Why?
|
Iron, Dietary | 1 | 2001 | 9 | 0.010 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 2001 | 23 | 0.010 |
Why?
|
Electric Stimulation | 1 | 2001 | 131 | 0.010 |
Why?
|
Cytodiagnosis | 1 | 2001 | 44 | 0.010 |
Why?
|
Hemoglobins | 1 | 2001 | 133 | 0.010 |
Why?
|
Vincristine | 1 | 2000 | 25 | 0.010 |
Why?
|
Cyclophosphamide | 1 | 2000 | 75 | 0.010 |
Why?
|
Prednisone | 1 | 2000 | 85 | 0.010 |
Why?
|
Doxorubicin | 1 | 2000 | 97 | 0.010 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 65 | 0.010 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2004 | 605 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2001 | 349 | 0.010 |
Why?
|
West Virginia | 1 | 1998 | 6 | 0.010 |
Why?
|
Linear Models | 1 | 1999 | 402 | 0.010 |
Why?
|
Cause of Death | 1 | 1999 | 210 | 0.010 |
Why?
|
Inflammatory Bowel Diseases | 1 | 1999 | 95 | 0.010 |
Why?
|
Liver Transplantation | 1 | 1999 | 207 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 1998 | 289 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 1999 | 243 | 0.010 |
Why?
|
Child | 1 | 1999 | 4174 | 0.010 |
Why?
|